What is HC Wainwright’s Forecast for Imunon FY2030 Earnings?

Imunon, Inc. (NASDAQ:IMNN) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Imunon in a report released on Thursday, February 5th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($1.45) per share for the year. The consensus estimate for Imunon’s current full-year earnings is ($1.68) per share.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a research note on Thursday, January 22nd. Brookline Capital Management reaffirmed a “buy” rating on shares of Imunon in a report on Wednesday, January 7th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $232.50.

Imunon Stock Performance

Imunon stock opened at $3.07 on Friday. Imunon has a fifty-two week low of $2.99 and a fifty-two week high of $41.22. The firm has a market capitalization of $9.42 million, a price-to-earnings ratio of -0.32 and a beta of 2.14. The stock’s fifty day moving average is $3.69 and its two-hundred day moving average is $4.93.

Imunon (NASDAQ:IMNN) last released its quarterly earnings data on Thursday, November 13th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.73) by $0.57.

Hedge Funds Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Riverview Capital Advisers LLC increased its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 193.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,364 shares of the company’s stock after buying an additional 22,649 shares during the quarter. Riverview Capital Advisers LLC owned about 1.41% of Imunon worth $176,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.